Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: An epidemiological survey of a large Japanese cohort

Hepatology Research

Volumn 41, Issue 6, 2011, Pages 530-541

  Miyazaki, Teruo ^a   Honda, Akira ^a   Ikegami, Tadashi ^a   Saitoh, Yoshifumi ^a   Hirayama, Takeshi ^a   Hara, Takashi ^b   Doy, Mikio ^c   Matsuzaki, Yasushi ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b Ibaraki Prefectural Institute of Public Health   (Japan)

^c IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Health examination; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Total cholesterol; Triglyceride

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; BODY MASS; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOLIPEMIA; LIPID BLOOD LEVEL; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUTRITIONAL STATUS; PRIORITY JOURNAL; VIRUS DETECTION;

EID: 79957550869     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00803.x     Document Type: Article

References (46)

1. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect 2002; 4: 1219-25.
3. Andre P, Komurian-Pradel F, Deforges S etal. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 6919-28.
4. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999; 96: 12766-71.
5. Diaz O, Delers F, Maynard M etal. Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol 2006; 87: 2983-91.
6. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 2009; 90: 1055-70.
7. Dubuisson J, Penin F, Moradpour D. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol 2002; 12: 517-23.
8. Miyanari Y, Atsuzawa K, Usuda N etal. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007; 9: 1089-97.
9. Huang H, Sun F, Owen DM etal. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA 2007; 104: 5848-53.
10. Gastaminza P, Kapadia SB, Chisari FV. Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 2006; 80: 11074-81.
11. Gastaminza P, Cheng G, Wieland S, Zhong J, Liao W, Chisari FV. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008; 82: 2120-9.
12. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225-32.
13. Dai CY, Chuang WL, Ho CK etal. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 2008; 49: 9-16.
14. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009; 50: 1030-7.
15. Siagris D, Christofidou M, Theocharis GJ etal. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006; 13: 56-61.
16. Maggi G, Bottelli R, Gola D etal. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 1996; 28: 436-40.
17. Marzouk D, Sass J, Bakr I etal. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007; 56: 1105-10.
18. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997; 261: 159-65.
19. Miyazaki T, Honda A, Ikegami T etal. The associated markers and their limitations for the primary screening of HCV carriers in public health examination. Hepatol Res 2009; 39: 664-74.
20. McIntyre N. Plasma lipids and lipoproteins in liver disease. Gut 1978; 19: 526-30.
21. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997; 157: 792-6.
22. Tassopoulos NC. EASL international consensus conference on hepatitis C Paris, 26-28 February 1999: consensus statement. J Hepatol 1999; 30: 956-61.
23. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002; 36: S179-84.
24. Shiffman ML, Diago M, Tran A etal. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4: 645-52.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
26. Tremblay AJ, Morrissette H, Gagne JM, Bergeron J, Gagne C, Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem 2004; 37: 785-90.
27. Sakurabayashi I, Kumasaka K. Laboratory Medicine Encyclopedia & Dictionary, 1st edn. Tokyo: Ishiyaku Publishers, Inc, 2008.
28. Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases. J Atheroscler Thromb 2007: 5-57.
29. Bray GA. Pathophysiology of obesity. Am J Clin Nutr 1992; 55: 488S-94S.
30. International guidelines for ethical review of epidemiological studies. Law Med Health Care 1991; 19: 247-58.
31. Okanoue T, Itoh Y, Minami M etal. Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts. Hepatol Res 2008; 38: 27-36.
32. Sanchez-Conde M, Berenguer J, Miralles P etal. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase. Clin Infect Dis 2006; 43: 640-4.
33. Pradat P, Alberti A, Poynard T etal. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36: 973-7.
34. Renou C, Halfon P, Pol S etal. Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels. Gut 2002; 51: 585-90.
35. Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS. Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS 2007; 21: 479-91.
36. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-34.
37. Hofer H, Bankl HC, Wrba F etal. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97: 2880-5.
38. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
39. Okamoto H, Mishiro S. Genetic heterogeneity of hepatitis C virus. Intervirology 1994; 37: 68-76.
40. Chuang WL, Yu ML, Dai CY, Chang WY. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006; 49: 99-106.
41. Gopal K, Johnson TC, Gopal S etal. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44: 335-40.
42. Perlemuter G, Sabile A, Letteron P etal. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-94.
43. Tardif KD, Waris G, Siddiqui A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol 2005; 13: 159-63.
44. Dharancy S, Malapel M, Perlemuter G etal. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334-42.
45. Honda A, Yamashita K, Miyazaki H etal. Highly sensitive analysis of sterol profiles in human serum by LC-ESI-MS/MS. J Lipid Res 2008; 49: 2063-73.
46. Ikegami T, Honda A, Nakamuta M etal. Non-invasive measurement of cholesterol metabolism in patients with HCV infection by using serum marker sterols. Hepatology 2009; 50: 946A-7A.